NAD+ precursor · Fact sheet
Nicotinamide mononucleotide
Also known as NMN · beta-NMN
NMN can affect NAD-related biomarkers in small human trials, but it is not an FDA-approved drug for anti-aging, energy, sleep, muscle performance, or metabolic disease. The clinical significance of reported signals remains uncertain.
What is Nicotinamide mononucleotide?
NMN is a naturally occurring nucleotide derivative used by cells to produce NAD+.
It is related to, but not interchangeable with, nicotinamide riboside or NAD+ itself.
Benefits people look for
Animal studies made NMN prominent in healthy-aging research, and small human trials have since examined metabolic, walking, sleep, and body-composition endpoints.
Most studies are short, use modest sample sizes, and measure many outcomes, so replication and clinical relevance matter.
What the evidence supports
- Small trials report increased NAD-related metabolites and some secondary signals in physical function or sleep.
- A controlled trial of a pharmaceutical NMN formulation found target engagement but did not establish a broad physiological rejuvenation effect.
All research areas
- NAD+ metabolism and aging biomarkers
- Walking and physical performance
- Sleep and fatigue
- Insulin sensitivity and body composition
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
More perceived energy, with initial insomnia and earlier waking
A person described initial stimulation and difficulty falling asleep, followed later by less of that effect but persistent earlier waking and perceived improvements in exercise and daytime energy.
Other lifestyle factors and coffee use were discussed. Subjective energy and sleep changes do not establish reversal of aging or a durable clinical benefit.
Read the NMN follow-up ↗Side effects & risks
- Short studies cannot rule out uncommon or long-latency harms.
- Commercial products may not match the identity, purity, or stability of material used in a clinical trial.
- The implications of long-term NAD-pathway manipulation in cancer, inflammatory disease, or other conditions are unresolved.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceHuman randomized trials are emerging and show biochemical effects, but results for walking, strength, insulin sensitivity, sleep, and other functional outcomes are not yet consistent enough for broad claims.
Selected research to read
Controlled study of walking, sleep, and related endpoints that requires replication and cautious interpretation.
Human target-engagement and physiological-outcomes trial in adults with overweight or obesity.
Small placebo-controlled study assessing short-term safety and selected outcomes.
What do the human studies show?
Selected research questions, not a complete inventory of indications or trials. Source checking is not independent clinical review. How we read the evidence.
| Study and people | Question and follow-up | Result and limits |
|---|---|---|
| MIB-626 NMN study Adults aged ≥45 with overweight or obesity 30 participants (actual) Randomized placebo-controlled trial; human | Nicotinamide mononucleotide versus Placebo 28 days Primary: Safety, NAD metabolism and physiological measures; endpoint hierarchy not extracted Phase: Not listed in this summary | Circulating NAD increased; strength, fatigability, aerobic capacity and stair-climbing changes did not differ significantly. Cannot tell us: Multiple short-term outcomes; no inference about lifespan. This formulation cannot represent every NMN product. Safety, uncertainty, and source detailsReported adverse events were similar between groups over 28 days. Limited to the studied population, formulation and follow-up. Funding/conflicts: Not confirmed in this summary; check the full paper. Source checked: 2026-09-18. Independent clinical review: not completed. |
What these results can and cannot tell us
Did the MIB-626 NMN study establish better physical function?
The selected short trial reported target engagement but no significant differences in the listed physical performance measures.
Limit: No conclusion about lifespan, every NMN formulation or every population follows.
Check the sources: MIB-626: NAD augmentation in adults (checked 2026-09-18)
Related, not equivalent: NAD+ · Nicotinamide riboside.
Compare research questions · Submit a source-based correction
FDA approval & research status
NMN has no FDA-approved drug indication for aging or any consumer wellness goal. Product-specific U.S. marketing status is a separate legal question from whether a health claim is clinically proven.
No FDA-approved use is documented in the records summarized on this page.
No FDA-approved drug use
NMN has small human trials and unresolved U.S. product-status questions, but no FDA-approved drug indication for aging, sleep, energy, or metabolic disease.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether any signal replicates in larger and more diverse populations
- Whether changes in biomarkers translate into fewer diseases or better function
- Long-term safety
- Which observed differences reflect NMN rather than chance across many measured endpoints
The takeaway
NMN is a real research molecule with early human data. It is not yet a proven anti-aging, sleep, metabolic, or performance intervention.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedRandomized NMN trial in older adults
Controlled study of walking, sleep, and related endpoints that requires replication and cautious interpretation.
- 2pubmedRandomized trial of the NMN formulation MIB-626
Human target-engagement and physiological-outcomes trial in adults with overweight or obesity.
- 3pubmedClinical trial of NMN in healthy adults
Small placebo-controlled study assessing short-term safety and selected outcomes.
- 4fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.